Medtronic plc
Medtronic plc (MDT) Stock News
The latest MDT headlines and market coverage — 4 recent stories, updated throughout the day.
- Zacks Investment Research·
Here's What Key Metrics Tell Us About Medtronic (MDT) Q1 Earnings
Medtronic reported $9.76 billion in revenue for the quarter ended July 2026, exceeding consensus estimates by 3.02% with a year-over-year increase of 13.7%. EPS of $1.45 surpassed the consensus estimate of $1.39 by 4.32%. Strong performance was driven by cardiovascular (+19.5% YoY) and diabetes (+16.9% YoY) segments, though the 'Other' category declined significantly. The stock currently holds a Zacks Rank #3 (Hold) rating.
- Zacks Investment Research·Neutral
Brokers Suggest Investing in Medtronic (MDT): Read This Before Placing a Bet
While Wall Street brokers maintain a Buy-equivalent average recommendation (ABR of 1.90) for Medtronic with 51.7% Strong Buy ratings, the article cautions that brokerage recommendations often suffer from positive bias due to vested interests. Medtronic's Zacks Rank of #3 (Hold) reflects unchanged earnings estimates, suggesting the stock may perform in line with the broader market rather than outperform.
- Zacks Investment Research·
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics
Medtronic is expected to report Q1 earnings of $1.39 per share, up 10.3% year-over-year, with revenues projected at $9.47 billion, representing 10.4% growth. Analysts forecast broad-based growth across most business segments, including Cardiovascular (+15.2%), Diabetes (+15.1%), and Neuroscience (+10.7%). The stock has outperformed the S&P 500 with +5.1% returns over the past month and carries a Zacks Rank #3 (Hold) rating.
- The Motley Fool·
I'm Calling It: Medtronic (MDT) Will Soar 40% by the End of 2026
Medtronic's stock has declined over 30% in the past five years due to cost pressures and competitive challenges, but analyst Leo Sun believes it could rise 40% to $121 by end of 2026. The company's recent diabetes unit spinoff, business restructuring focused on higher-margin cardiovascular and neuroscience portfolios, and strong revenue growth (8.4% in fiscal 2026) position it for recovery. Trading at 18x forward earnings with a 3.3% dividend yield and potential Dividend King status next year, Medtronic could attract significant investor attention.